TRANSCRIPT

Q3 2026 — Prepared remarks

Q3 2026PDF · 14 pages167 KB
1
Philip Morris International Inc.
2026 Third-Quarter Conference Call
October 21, 2026
JAMES BUSHNELL
(SLIDE 1.)
Welcome. Thank you for joining us. Earlier today, we issued a press release containing
detailed information on our 2026 third-quarter results. The press release is available
on our website at www.pmi.com.
(SLIDE 2.)
A glossary of terms, including the definition for smoke-free products as well as
adjustments, other calculations and reconciliations to the most directly comparable
U.S. GAAP measures for non-GAAP financial measures cited in this presentation are
available in Exhibit 99.2 to the company's Form 8-K dated October 21, 2026, and on
our Investor Relations website.
(SLIDE 3.)
Today’s remarks contain forward-looking statements and projections of future results.
I direct your attention to the Forward-Looking and Cautionary Statements disclosure
in today’s presentation and press release for a review of the various factors that could
cause actual results to differ materially from projections or forward-looking statements.
I’m joined today by Massimo Andolina, Group Chief Financial Officer.
Massimo, over to you.

-- 1 of 14 --

2
MASSIMO ANDOLINA
(SLIDE 4.)
Thank you, James, and welcome everyone.
We delivered excellent performance in the third quarter, with continued volume
momentum putting us firmly on track for a sixth consecutive year of total shipment
growth and yet another year of best-in-class results in 2026.
The strong underlying momentum of our smoke-free business continued, with IQOS
HTU 	shipments 	at the 	high 	end 	of 	our 	expectations 	and 	accelerated 	growth
fundamentals across all three of our flagship brands. Coupled with stand-out
combustibles performance, we achieved +7% organic growth in Q3 net revenues and
more than +10% growth in operating income, despite challenging comparisons on
smoke-free shipments and incremental cost pressures, notably due to the ongoing
conflicts in the Middle East and Ukraine. Q3 adjusted OI exceeded $5 billion for the
first time, while our adjusted OI margin reached close to 45%. Our strong operational
performance supported better-than-expected adjusted diluted EPS growth of +6%
excluding currency to a record quarterly level of $2.36.
IQOS continued to deliver strong and broad-based progress, with adjusted IMS
volume growth increasing to +7.1% in the quarter, or +10% excluding Japan and
Poland, where we faced specific headwinds from the impact of excise-driven pricing
and the characterizing flavor ban respectively.
In nicotine pouches, ZYN’s Q3 shipment growth accelerated in international markets
and reached +4% in the U.S., or +13% excluding the special promotional activity of
September 2025. This performance was supported by the ongoing roll-out of new
variants, as we invest significantly in the accelerated expansion of our product offer
and align the portfolio value proposition over the second half of this year. We are
pleased with the initial consumer reaction and sequential increase in category share,
even as we have yet to reach full commercial deployment of the first wave of
expansion. We remain focused on further strengthening the brand, building consumer
awareness of the expanded portfolio and continuing to invest behind the significant
growth opportunity ahead.
In e-vapor, VEEV continued its outstanding progress with a step-up in shipment growth
to +62%. We delivered strong performance across key markets and continued to build
our leading position in Europe, the primary international profit pool.

-- 2 of 14 --

3
Our combustible business delivered a stand-out Q3 performance, exceeding our
expectations through a combination of stable volumes, high single-digit pricing and a
specific benefit from the restructuring of distribution terms in certain markets. Volumes
were especially resilient in markets where smoke-free alternatives remain unavailable
or have limited presence, while the continued strength of our brand portfolio, led by
Marlboro, supported category share gains and further margin expansion. This is in line
with our objective of maximizing combustibles value over time to support the growth
of our smoke-free business.
Our overall year-to-date performance further demonstrates the sustainability of our
growth model. We continue to expect another year of high-quality, best-in-class
volume, sales and profit growth, as we continue to invest behind our leading smoke-
free platforms to drive long-term value.
(SLIDE 5.)
Turning now to our headline financials for the third quarter.
We delivered shipment volume growth of +0.6%, outperforming a broadly stable
industry, despite unfavorable comparisons on HTUs. Together with robust pricing and
favorable category mix, this drove organic net revenue growth of +7.1%, or +5.5% in
dollar terms, to reach $11.4 billion.
Gross profit grew organically by more than +8%, and adjusted operating income
increased +10.5% organically and +9.6% in dollar terms. This reflects strong top-line
growth 	and 	effective 	cost 	management, 	even 	as 	we 	accelerated 	our 	growth
investments, notably in the U.S.
Adjusted diluted EPS increased +5.4% to a new quarterly high of $2.36. This includes
an unfavorable currency impact of 1 cent due to dollar strength and lower positive
transactional impacts than previously expected, mainly due to the strengthening of the
Russian Ruble. As flagged last quarter, this growth also includes an unfavorable
comparison against a low tax rate in the prior year period, which reduced Q3 EPS
growth by approximately 4 percentage points.
(SLIDE 6.)
Our outstanding year-to-date results further demonstrate the strength and quality of
our business fundamentals, with shipment volume growth of +0.5%, strong pricing and
favorable category mix. This drove organic net revenue growth to +5.9%, or +8.2% in
dollar terms, bringing year-to-date net revenues to nearly $33 billion.

-- 3 of 14 --

4
Adjusted gross profit increased by +7.1% organically, while adjusted OI grew by +7.7%
organically and +10.6% in dollar terms, reaching more than $14 billion. We delivered
adjusted diluted EPS of $6.52, representing growth of +8.4% excluding currency and
+11.8% in dollar terms.
(SLIDE 7.)
Turning to shipment volumes, we achieved solid growth in both the third quarter and
year-to-date. Consistent with recent years, the structural growth of our smoke-free
portfolio more than offset declines in combustibles, and we are firmly on track to
achieve our sixth consecutive year of growth.
Smoke-free shipments increased by +2.7% in the quarter despite the strong prior-year
comparison, and by +6.4% year-to-date, driven by IQOS. We continue to expect high
single-digit growth in smoke-free adjusted IMS volumes and shipments for the year,
with the latter subject to year-end inventory movements.
IQOS HTU shipments reached 41.5 billion units in Q3, with year-to-date growth of
+6.7%. We now expect HTU shipment growth to be slightly below adjusted IMS growth
for the full year, with the Q3 dynamic of adjusted IMS growing faster than shipments
to continue in Q4, notably due to the in-year phasing impact of price changes in Japan.
Q3 shipment growth was supported by a wide range of markets, including Germany,
Greece, Spain, Indonesia, the UK, the Netherlands and Global Travel Retail, all of
which delivered strong double-digit progression.
Oral smoke-free volumes increased by +1.8% in the quarter, supported by our
readiness and ability to introduce new product variants in the U.S., alongside an
acceleration in international ZYN growth and share gains in Swedish snus. E-vapor
shipments grew by a remarkable +62%, demonstrating the increasing scale and
importance of our multicategory portfolio, and VEEV’s role within it.
Cigarette shipments were flat in the quarter despite strong pricing, outperforming an
industry decline of 1.1%. This reflects both the strength of our brands and the
resilience of the category in markets where smoke-free products are banned or have
limited presence such as Turkey, Indonesia and Egypt. On a year-to-date basis,
cigarette volumes declined by 1.2%. While the markets driving this better-than-
expected performance generate an unfavorable geographic mix, the continued
resilience of our combustible portfolio means we now expect full year cigarette
volumes to decline by a similar level, subject to year-end inventory movements.

-- 4 of 14 --

5
(SLIDE 8.)
We continue to generate strong top-line growth from the fundamental pillars of our
business model, namely volume growth, pricing power and the mix benefit of favorable
smoke-free unit economics.
Year-to-date, pricing remained the largest contributor, adding +6.2 points of growth.
This reflects continued combustible strength, with pricing of +9.1%, together with a
positive contribution from our smoke-free portfolio, including low single-digit pricing on
IQOS HTUs.
The increasing contribution of smoke-free products in our international business
provided a further +1.5 points of growth, notwithstanding a lower impact in Q3 due to
timing factors. This was partly offset by a 0.6 point headwind from the U.S., driven
predominantly by the impact of lower ZYN shipment volumes and challenging
comparisons earlier in the year, with these headwinds moderating significantly in the
third quarter.
Combustible geographic mix and other factors reduced growth by 1.7 points. These
headwinds were partially mitigated in Q3 by the impact of restructuring of certain
distribution terms I mentioned earlier, which we do not expect to be significant in the
fourth quarter.
As a result, year-to-date organic net revenue growth reached +5.9%, and +7.1% for
Q3. Currency contributed a further +2.3 percentage points year-to-date, bringing
reported net revenue growth to +8.2%.
(SLIDE 9.)
Moving further down the P&L, our adjusted operating margin organically expanded by
+60 basis points year-to-date, and +130 basis points in Q3, reaching a very strong
level of almost 45% in the quarter.
Gross margin expansion remained the primary driver, contributing +80 basis points in
both Q3 and year-to-date, bolstered by strong pricing, favorable smoke-free mix,
increasing 	scale 	benefits 	across 	our 	smoke-free 	business 	and 	manufacturing
productivity gains.
At the same time, we continue to invest strongly behind future growth opportunities.
While SG&A organically increased by less than net revenues in Q3, this reflects the
ongoing benefits of our G&A productivity initiatives and a favorable comparison against
the 	prior-year 	period 	which 	included 	certain 	combustible-related 	items. 	Both

-- 5 of 14 --

6
international and U.S. smoke-free commercial investments continued to grow ahead
of the top line, accelerating versus the second quarter.
For the full year, we expect SG&A to grow broadly in line with net revenues, as we
continue to work on our back-office costs while strongly increasing commercial
investments behind our growth platforms and consumer-facing initiatives across the
world. This includes increased investments in the U.S. to support our ZYN portfolio
expansion and competitiveness.
Indeed, our productivity program continues to deliver strong results. We have now
generated more than $2 billion of cumulative gross cost savings across both COGS
and SG&A since 2024, achieving our 3-year objective ahead of schedule.
(SLIDE 10.)
Focusing now on our international business, which continues to be the primary engine
of group performance and represents 93% of our year-to-date net revenues.
International smoke-free delivered excellent year-to-date results, with organic growth
of almost +10% in net revenues and +12% in gross profit driving +120 basis points of
gross margin expansion to 70%. This reflects the continued growth and increasing
profitability of IQOS, with additional contributions from our expanding smoke-free
portfolio, particularly VEEV. As expected, Q3 growth was slower due to shipment
timing comparisons and related category mix. Importantly, IQOS gross margins
continued to expand meaningfully, despite additional cost disruption in Ukraine.
Our 	international 	combustible 	business 	also 	delivered 	a 	strong 	year-to-date
performance. Higher category share, robust pricing and efficient execution drove
organic net revenue growth of +5.2% and gross profit growth of +7.4%, supporting
+140 basis points of organic gross margin expansion.
Together, our international smoke-free and combustible businesses drove +7.0%
organic net revenue growth and +9.1% gross profit growth, with +140 basis points of
gross margin expansion to 68.8%. This performance supported international organic
OCI growth of around +11% in both Q3 and year-to-date, comfortably exceeding the
targeted OI growth rates for total PMI.
(SLIDE 11.)
Now focusing on international smoke-free, we drove +8.6% growth in total adjusted
IMS year-to-date, including an acceleration to +8% in Q3 and despite the impacts from

-- 6 of 14 --

7
Japan and Poland. Excluding these two markets, growth was +11.8% year-to-date,
consistent with the strong growth rates delivered over recent years.
Importantly, our smoke-free portfolio continues to outgrow the comparable industry by
approximately 1 percentage point, with our share increasing to 62%, reflecting the
increasing strength of our multicategory strategy. I also note that our total international
market share of cigarettes and HTUs exceeded 30% in the quarter for the first time,
underscoring the combined strength of our smoke-free and combustible portfolios.
(SLIDE 12.)
IQOS remains the driving force behind our smoke-free growth. Adjusted IMS volume
growth accelerated from +5.1% in Q2 to +7.1% in the third quarter. We are especially
pleased with the delivery of +7.7% growth year-to-date, despite the known headwinds
in Japan and Poland.
Excluding these two markets, adjusted IMS growth remained around +10% in the
quarter and almost +11% year to date, consistent with the strong underlying trajectory
of the business and the durability of demand across our geographic footprint.
Key European geographies, including Italy, Greece and Spain, all delivered double-
digit adjusted IMS growth year-to-date, complemented by excellent performance in
markets such as Indonesia, Mexico, the Philippines, Saudi Arabia and Taiwan, as well
as Global Travel Retail, highlighting the increasing geographic diversification of the
IQOS business.
Our device and consumables pipeline remains active, supporting both legal-age
consumer acquisition and brand loyalty. We continue to enrich our premium TEREA
and LEVIA HTU offerings with new taste experiences. Our mainstream-priced variants
of DELIA and SENTIA are also supporting acquisition and exceed the size of our
closest category competitor. In addition, the expansion of our alternative heating
technology BONDS by IQOS is ongoing, and is resonating well with harder-to-reach
entrenched smokers in initial launch areas.
(SLIDE 13.)
The strength of IQOS is exemplified by excellent key city offtake share progress across
the world, a strong indicator of national-level growth potential.
We recorded further strong Q3 share gains across established IQOS markets
including Germany, Greece, Italy, Japan, Romania, the Netherlands and the UK,
alongside Global Travel Retail. We also continue to see very promising momentum in

-- 7 of 14 --

8
newer growth markets such as Mexico, Indonesia and Taiwan, in which IQOS
increased its national category share to more than 80%.
(SLIDE 14.)
Switching to VEEV, whose momentum remains very strong. Year-to-date shipment
volumes increased by +68% to 4.0 billion equivalent units. This includes continued
gains and increasing category leadership across European markets, with VEEV further
extending its lead over established competitors as the number one closed pod brand
in the region. Elsewhere, we continue to see promising growth in markets such as
Egypt, Malaysia, Global Travel Retail and in South Korea following its recent launch.
The business continues to benefit from our unique multicategory deployment using the
unparalleled commercial infrastructure and consumer reach of IQOS, while also
benefitting from the structural shift toward closed pod systems across international
markets. This trend aligns with our portfolio and commercial strategy, as we drive
momentum with meaningful innovation, such as the current roll-out of our new VEEV
ONE+ device.
(SLIDE 15.)
Moving now to ZYN, which continues to generate promising growth in international
markets as we invest to build the category. Year-to-date international shipment
volumes reached 1.5 billion pouches, representing growth of +6.3% on a like-for-like
basis. This includes a sequential step-up to +7% in Q3, supported by improving
sequential trends in Sweden following the launch of new ZYN flavor variants. Strong
double-digit progression continued in markets such as Poland, Global Travel Retail
and Mexico, partly offset by inventory movements in the UK and Pakistan.
Growth was supported through portfolio innovation such as ZYN Black Menthol,
continued category expansion and growing consumer adoption across a broad range
of markets. ZYN’s year-to-date ex-Nordics IMS growth reached +30%, outperforming
the industry and growing ahead of shipments.
(SLIDE 16.)
In Europe, our most advanced multicategory region, combined smoke-free IMS
volumes for IQOS, ZYN and VEEV increased by approximately +8.6% year-to-date
and +8.9% in Q3, reflecting strong momentum.
IQOS adjusted IMS growth strengthened to +6.0% in Q3, notably driven by an
acceleration in Germany and Spain. Performance was broad-based across the region,

-- 8 of 14 --

9
with strong growth continuing in Italy, Greece, the UK and Bulgaria, more than
offsetting the impact of disruptions in Ukraine. Excluding headwinds in Poland due to
the characterizing flavor ban implementation earlier this year, adjusted IMS growth in
Europe was around +8%.
Our other smoke-free categories continue to scale rapidly. VEEV shipment volumes
increased by +75% year-to-date, and +66% in Q3, with outstanding growth in
Romania, Greece, Germany, France, Bulgaria and Spain. ZYN volumes reached 1.0
billion pouches year-to-date, accelerating to almost +6% growth in Q3 on a like-for-
like basis as we invest behind the category. This was supported by strong progress in
markets such as Poland, Austria and Finland, in addition to the better Swedish delivery.
(SLIDE 17.)
In Japan, IQOS fundamentals remain strong amidst the volatility of the two-step excise
increase on heated tobacco this year. Following a Q2 decline in adjusted IMS volumes
due to pantry de-loading, HTUs returned to growth in Q3 with an increase of +3.4%.
As in Q1, before the April excise-driven price increase of JPY40 per pack, Q3 IMS
growth includes a favorable impact from consumer pantry-loading ahead of our JPY20
increase in October. Excluding this impact, underlying growth was +1.3%, as
consumers gradually adjust to higher prices in an environment where combustible
cigarettes did not yet face any excise change. This remains in line with our
expectations and we continue to expect growth for the year, notwithstanding a likely
softer Q4 as pantry-loading again reverses and consumers adapt to a further price
increase.
Our adjusted heat-not-burn category share remained stable at approximately 68%
despite taking more pricing than competitors in April, highlighting the strength of the
IQOS proposition.
Looking forward, the excise calendar for the next 3 years looks less disruptive, with
moderate increases on both combustibles and heated tobacco alike each April. While
the April 2027 increase will mark the third change in 12 months, with a potential
cumulative impact on the consumer, we remain excited about the category’s mid-term
growth potential in Japan. Although heated tobacco continues to account for over 50%
of total nicotine offtake, there remains a substantial pool of smokers yet to switch,
supporting our confidence in the capacity for strong IQOS performance in the years
ahead.

-- 9 of 14 --

10
(SLIDE 18.)
Turning now to the U.S., where we delivered strong financial performance in Q3,
supported by ZYN volume growth of +4.2% to 3.2 billion pouches, or +13% excluding
the impact of one-off promotions in September last year. Sequentially, shipments
increased by +10% versus Q2, reflecting category expansion and the ongoing launch
of new portfolio variants, which have contributed to an improvement in our category
share and should position us well for future growth. We expect Q4 shipment volumes
to be broadly in-line to modestly above Q3 levels, as we continue to expand distribution
and support the rollout of the enhanced portfolio.
U.S. net revenues increased by almost +23%, and gross profit by +24%, with gross
margins expanding organically by +60 basis points to 64.4%. This was supported by
favorable 	pricing 	comparisons 	against 	the 	same 	prior 	year 	promotions,
notwithstanding the impact of higher manufacturing overheads and start-up costs from
our new ZYN facility in Colorado, which is gradually ramping up production. Adjusted
OCI grew by +1.5%, as we meaningfully increased commercial investments to support
the expansion of our ZYN portfolio.
(SLIDE 19.)
Supported by our readiness and ability to launch new products, we are taking
significant actions across the second half of this year to strengthen ZYN’s competitive
position as the leading and premium U.S. smoke-free brand.
The first action is the expansion of the ZYN offering in two waves to address a broader
range of legal-age nicotine consumer preferences.
The first wave of expansion comprises the higher-nicotine moist range of ZYN ULTRA
and an expanded flavor line-up for our flagship dry portfolio, which are now
approaching full distribution. While we are still building consumer awareness around
our new range, especially for ZYN ULTRA, we are encouraged by the initial consumer
reaction. Indeed, following several quarters of volume progress below the category
growth rate, ZYN’s category offtake share increased by an estimated 1.4 points from
June to September, demonstrating the incremental contribution of the new variants
and interest from competitor pouch consumers.
We also began shipments of the second wave of product introductions in the quarter,
with new flagship variants in both 1.5mg and 8mg strengths further broadening the
consumer offer and supporting our objective of encouraging legal-age nicotine users
to switch to the category.

-- 10 of 14 --

11
The second important action is to align the value proposition across the portfolio and
optimize ZYN’s per-pouch price positioning. We began this process over the summer
with the launch of ZYN ULTRA in 20-pouch cans, and starting in October we are now
transitioning our 1.5mg, 3mg and 6mg flagship variants from 15 to 20 pouches. These
variants represent the large majority of our volumes, and as we work to execute the
change smoothly for both consumers and trade partners, we expect the transition to
be largely complete in the fourth quarter.
As we flagged at Q2 earnings and in subsequent communications, these actions are
accompanied by an H2 step-up in investments. Total U.S. segment SG&A increased
significantly to around $370m in Q3, and we expect a further exceptional sequential
increase of around 10% in Q4. This reflects increased consumer communications to
build awareness of the expanded portfolio and enhanced value proposition, together
with the ramp-up of our "When it Clicks" brand campaign. Looking beyond Q4, we view
the Q3 level of spend to be sufficient to support the brand.
The transition to 20-pouch cans represents a significant investment in consumer value,
which - all else equal – translates into approximately 25% less revenue-per-pouch.
Combined with additional short-term support on the existing 15-pouch variants to
manage the sell-out at retail, this will impact Q4 net revenues.
Indeed, taking the aggregate impact of these actions and the expansion of our
manufacturing capacity to support future growth, Q4 will be a unique quarter of
investment. We expect an abnormally low level of U.S. profitability in the fourth quarter,
with adjusted OCI around zero or slightly negative.
Our leading global position and strong growth profile reflects continuous investment
for mid and long-term growth, and we are excited to be implementing these significant
improvements to our ZYN consumer offer. With a fast-growing category and ZYN’s
leading brand equity, we believe we are positioning the brand for strong and
sustainable growth over the coming years.
(SLIDE 20.)
Finally, turning to combustibles, which posted an exceptional Q3 performance. Pricing
remained a key driver, reaching +8.9% in the third quarter and +9.1% year to date,
with broad-based contributions across markets including Turkey, the Philippines,
Indonesia and Poland. We now expect full-year pricing of above 8%, with the net
revenue impact partially offset by a more unfavorable geographic mix.
Despite this strong pricing, our portfolio increased Q3 international category share by
0.4 points to 25.9%, driven by Marlboro which reached a record high of 11.4%.

-- 11 of 14 --

12
This strong share performance and robust pricing drove another quarter of excellent
profitability, with international combustible gross profit increasing by +9.8% in Q3 and
+7.4% year to date.
(SLIDE 21.)
This brings me to our outlook for the full year, where we are targeting a second
consecutive year of double-digit adjusted diluted EPS growth in dollar terms.
Indeed, following our strong first nine months, we are on track for another year of
excellent performance as we continue to invest behind smoke-free growth.
We now expect growing total shipment volumes for the year, making 2026 our sixth
consecutive year of growth.
For net revenues, we continue to forecast +5% to +7% organic growth. Moreover,
given the strong year-to-date delivery and our expectation for a robust fourth quarter
led by international smoke-free, we believe the business could deliver in the middle or
upper half of this range.
At the operating income level, we continue to expect organic growth of +7% to +9%,
reflecting strong inherent margin expansion from our top-line performance and
productivities, and despite our substantial ongoing investments in SFP internationally
and in the U.S. Our forecast range for currency-neutral adjusted diluted EPS growth
also remains at +7.5% to +9.5%. With a favorable currency impact at prevailing
exchange rates of approximately 18 cents, notably including recent weakness in the
Euro, this results in an adjusted diluted EPS range of $8.29 to $8.44, representing
growth of approximately +10% to +12% in dollar terms. However, considering the
significant H2 step-up in U.S. investments and the cost impact of ongoing geopolitical
tensions, we see the full-year delivery more likely to be at the midpoint or lower half of
both brackets.
Although the inflationary outlook remains uncertain, most notably the persistence of
energy-related inflation linked to the conflict in the Middle East, the prices of certain
inputs have begun to reflect the increases in energy and shipping costs. While we are
less exposed than many other areas of consumer goods and this remains manageable
overall, these factors were a headwind in the third quarter and are expected to evolve
further in Q4 as a greater proportion of increased input prices flow through. Overall,
we estimate the impact on full-year adjusted diluted EPS growth to be around half a
percentage point, in addition to a similar sized headwind from disruptions in Ukraine.
This results in a combined impact of approximately 1 point of growth for the year.

-- 12 of 14 --

13
For Q4 more broadly, we anticipate a strong net revenue and OCI performance from
our international business, including a reacceleration in smoke-free performance. We
expect continued robust adjusted IMS growth and HTU shipment volumes of 39.5 to
40.5 billion units, consistent with our comments on shipment phasing. In contrast, this
will be a unique quarter of elevated investment and portfolio transition for the U.S., for
the reasons I explained. Despite this special quarter for the U.S., we expect a strong
delivery for the group overall, as captured in our full-year outlook.
We also expect to generate a record level of approximately $13.5 billion in operating
cash flow, testament to our strong cash flow generation. This provides substantial
flexibility to invest behind future growth while continuing to deleverage and deliver
attractive shareholder returns.
(SLIDE 22.)
Let me now conclude with a few key takeaways.
Our year-to-date performance reflects the quality of our underlying fundamentals,
positioning us for another year of superior top and bottom line growth as we continue
to invest substantially behind future opportunities.
This reflects the durability of our model, supported by category-leading brands, strong
pricing power, disciplined cost management and the increasing scale of IQOS, ZYN
and VEEV.
We remain a highly cash-generative business, with an unwavering commitment to our
progressive dividend policy and to rewarding shareholders. In September we raised
our dividend for the 19th consecutive year to $6.40 per share, with another increase
of almost 9%.
Looking ahead, we remain confident in our mid and long-term trajectory, which reflects
the unique strengths of PMI's growth model: structural smoke-free momentum built on
science, innovation, commercial strength and brand building, allied to combustible
resilience and effective reinvestment. We look forward to sharing more on these
elements at our next Investor Day, which we plan to hold in Q2 next year.
(SLIDE 23.)
Thank you. We are now happy to answer your questions.

-- 13 of 14 --

14
JAMES BUSHNELL
(SLIDE 24.)
That concludes our call today. Thank you for joining us. If you have any follow-up
questions, please contact the Investor Relations team. Thank you again and have a
nice day.

-- 14 of 14 --